Company insight
Leveraging the ‘D’ in CDMO to enhance innovation
Contract development and manufacturing organisations (CDMOs) can play a vital role in the R&D of medical devices, as well as provide manufacturing scale and capacity. Jim Banks talks with Brett Landrum, vice president and general manager, Global Medical at Phillips Medisize, a Molex company, that recently celebrated its 60th anniversary, about the elements that go into creating relationships that foster innovation.
cquired by global electronics and connectivity solutions company Molex in 2016, Phillips Medisize has grown into a key partner to many of the largest pharma, medical device and in vitro diagnostic companies in the world. We asked Landrum how CDMOs can lean into the design and development “D,” as well as the manufacturing “M” to enhance innovation and add value to their customers.
A
What is the vision of Phillips Medisize, and how has it contributed to your role as a trusted partner in drug delivery device design and development for leading pharma and medical companies? “Our vision is to be the preferred partner of choice for leading global customers and to create innovative products that help people around the world live healthier, more productive lives. As a result, we always start with the idea of improving patients’ lives and the many ways to achieve that. You can make improvements to existing therapies, but there is a place for disruptive innovation, and some companies will come up with solutions that can completely change the standard of care. We really take our vision and that opportunity to heart, so everything we do is about improving the lives of patients globally. That is why we get up in the morning. “To achieve that goal, we focus on how best to strategically partner with the leading pharma and medtech companies that are aligned to our goals and vision. They need a strategic partner with the know-how and passion to make a difference, and that is where a CDMO with our track record and experience comes in. Instead of describing our offering as ‘end- to-end’, we say we are with our customers from ‘discovery to delivery’ – discovery of
Brett Landrum, vice president & general manager, global medical, Phillips-Medisize
the breakthrough innovation through delivery of final device.”
CDMOs can clearly play a big role in optimising manufacturing processes, but how can they influence the R&D process too? “With 23 manufacturing plants across three continents, we offer global production capabilities that allow us to scale quickly. Equally important to helping customers and patients is the fact that our manufacturing facilities are complemented by seven innovation centres around the globe where our teams of engineers and scientists are constantly challenging standards of care. Whether it’s an autoinjector requiring specialised lyophilization, an on-body pump with unique delivery requirements, or an API that needs formulation for inhalation along with device development – our experts collaborate with our customers to design, develop and make meaningful improvements. We also bring an extensive track record and innovative platform technologies that may enable us to bring that device to market faster.”
“In terms of maintaining an innovation mindset, we are intentional about remaining open to interesting ideas. That is one of the advantages of being a Molex company, which is part of Koch. The family of companies that Koch owns works across many industries, so we tap into innovation across the spectrum and bring the relevant ideas into the highly regulated pharma
World Pharmaceutical Frontiers /
www.worldpharmaceuticals.net
environment, where innovation usually happens at a more measured pace than in the consumer sectors.”
How can a CDMO ensure a cohesive transition from R&D to manufacturing?
“Instead of focusing solely on large-scale, high-volume manufacturing, we frequently engage in early-stage design work and then strategically build a path to commercial manufacturing. After all, some of our largest commercial manufacturing programs started as tiny R&D ideation sessions years ago. By integrating our manufacturing insights into the development process, we help our customers achieve a balance between innovative design and practical manufacturability. This integration helps to reduce the risk of costly redesigns.”
Time-to-market is a crucial factor, so how does Phillips Medisize help to accelerate the design and production of new drug delivery devices? “When you have a product or idea that will improve lives, you want to get it to market as quickly as possible. While some customers engage us to accelerate a specific phase of product development, our strength lies in collaborating with them across the entire timeline. For example, this comprehensive approach may allow for a smoother regulatory path or faster transition to automated production lines, ultimately speeding up time to market. “Product design and development is challenging, and roadblocks are inevitable. No program runs flawlessly from start to finish, and it’s in these moments that our company culture truly comes into its own and shines.” ●
www.phillipsmedisize.com 23
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58
